In conclusion, there is much evidence from several CVOTs that indicate cardio-reno-metabolic benefits using an SGLT2-i and GLP-1 RAs in patients with metabolic syndrome at very high/high CV risk or with atherosclerotic cardiovascular diseases. The gene discussed is SLC5A2; the disease is metabolic syndrome.